Good morning. This is Joseph Gartner, President of Aerpio Pharmaceuticals. I am very pleased to share an update on our 2020 progress with our investors. As announced previously, we started our Phase II trial of a topical ocular formulation of razuprotafib in glaucoma, for which we expect top line results by the end of year 2020 ahead of the earlier guidance we provided. As announced on June 24, we have over 20 clinical sites actively screening patients for the trial with a target enrollment of 195. We now have 170 patients enrolled, including those in the 28-day washout period and those in the drug treatment period. Based on these results, we are well on our way to meet our target of 195 patients completing the 28-day drug treatment regimen. We expect – and we expect the trial to be fully enrolled by October. Our investigators have been extremely enthusiastic to return to their practices after the lifting of the COVID quarantine in large regions of the country. And they are very interested in working with an agent that has a novel mechanism of action that lowers the resistance to fluid outflow via Schlemm’s canal, thereby lowering intraocular pressure, which I will refer to as IOP. Notably, this IOP lowering signal was seen in two sequential Phase II studies with a subcutaneous formulation of razuprotafib in ocular normotensive patients, who had diabetes. As stated above, we remain on track to report top line results from this Phase II glaucoma trial in the fourth quarter of 2020. You may recall that we opted to progress into Phase II after a highly encouraging result in a small Phase I trial for 43 glaucoma patients who had baseline interocular pressure ranging from 27 to – 17 to 27 millimeters of mercury at a 1.58-millimeter mercury incremental reduction in the diurnal IOP on day seven when razuprotafib was added once-daily on top of existing standard of care prostaglandin therapy. Our product candidate was associated with a statistically significant reduction in IOP on top of standard of care prostaglandin. And these effects were not only clinically meaningful, but deemed to be potentially best-in-class for adjuvant therapy by our clinical advisers. Equally important, the data suggested a favorable tolerability profile for a topical drug candidate, including low incidence of hyperemia or red eye and no systemic safety concerns. So the tolerability profile of razuprotafib is a clear differentiator in today’s market. At this point, I want to switch gears to our COVID program. We are also making progress with our subcutaneous formulation of razuprotafib in the I-SPY trial for the treatment of acute respiratory distress syndrome, or ARDS, in COVID-19 patients. The I-SPY COVID-19 trial is a platform trial run in collaboration with an outside network of investigators, which includes four active drug arms and a control remdesivir arm. Aerpio’s razuprotafib was one of the four product candidates selected to be in the trial and the only candidate from a biotech company as the other three candidates are from major pharmaceutical companies. The goal of the study is to identify agents that will result in substantial improvements to the clinical condition of participants with critical COVID-19. Patients to be enrolled are classified as critical because they are already either on high flow oxygen or incubated on a ventilator. To learn more about this study and its design, please feel free to look up razuprotafib on www.clinicaltrials.gov. Now in addition to the I-SPY trial on August 4, 2020, we announced funding of up to $5.1 million from MTEC, the medical technology enterprise consortium funded by the U.S. military to initiate a second clinical trial with razuprotafib, which is designed to assess its potential to prevent the acute respiratory distress syndrome in patients with moderate to severe COVID-19 symptoms. The MTECH trial is a stand-alone study managed by us at Aerpio that will evaluate earlier stage patients, i.e., moderate to severe COVID-19 patients. These patients are presenting prior to requiring high flow oxygen or incubation. The endpoints will include proportion of subjects alive and respiratory failure free at day 28, also the length of hospitalization from baseline to day seven and the length of hospitalization from baseline to day 28 or death. Trial startup activities are progressing rapidly. The two trials are complementary as they will assess razuprotafib across a range of disease severity in COVID-19 patients, potentially demonstrating the ability to prevent the ARDS in moderate to severe patients and/or treat ongoing respiratory distress in the critically ill patients. The two-trial approach will optimize our ability to determine how to best utilize razuprotafib to potentially save lives in patients with COVID-19. As background, the key COVID binding receptor is the ACE2 receptor, which has been widely published, which is expressed on both pulmonary epithelium and endothelial cells, indicating that both tissues are disease targets for the virus. Our scientific hypothesis about razuprotafib is that restoring Tie2 activation enhances endothelial cell function and vascular stability to improve outcomes in COVID-19 by preventing the vascular leak of both the fluid and the inflammatory cells into the lung. The vascular stabilization provided by razuprotafib may potentially prevent or ameliorate the devastating respiratory distress that these patients often experience. Outside scientists have conducted significant preclinical work to demonstrate that Tie2 is expressed in the vasculature in the lung, and we believe that active Tie2 is essential for maintaining endothelial cell function and vascular stability in the lung and throughout the rest of the body. Now fortunately, Aerpio currently has the financial resources to support the completion of these clinical trials with the cash and cash equivalents of $44.9 million as of June 30, 2020. Gene will provide more details on the financials at the end of this call. Now I will discuss the market opportunities for razuprotafib. We believe that glaucoma is an attractive commercial opportunity. As many of you know, glaucoma is a serious eye condition affecting three million patients in the U.S. We estimate that the dollar value of the total global market for adjuvant therapies is greater than $3 billion. Simply capturing one third of that market could produce a $1 billion product. If our drug is truly disease-modifying, as we expect, then the market share could go significantly higher. More background on the glaucoma market is provided in our 10-Q filing. Based on published Science, supporting the role of Tie2 in the maintenance of Schlemm’s canal, we believe that razuprotafib has the potential to become the first disease-modifying therapy for glaucoma. And we are very enthusiastic about this opportunity for our shareholders. Now in addition to glaucoma, the opportunity to address the ongoing COVID pandemic with a unique treatment that may render the disease less lethal could be profoundly important to patients, their families and simultaneously, a significant source of value to our shareholders. The outside thought later support we have received has been remarkable, with both the I-SPY network and the U.S. military supporting our programs. This third-party validation is critical in helping us move forward as we are treating a new disease with a novel biological mechanism. We expect to announce progress on both trials in the first half of 2021. Positive results will have a beneficial impact on the company and our shareholders and hopefully, will transform how these patients are treated. As reported previously, Aerpio has pioneered the field of Tie2 activation by developing both small molecule and antibody drug candidates that activate Tie2. Tie2 is a receptor tyrosine kinase, uniquely expressed in vascular endothelial cells in all vasculature and is also expressed in Schlemm’s canal in the front of the eye. We have learned over the years how Tie2 activation stabilizes vasculature in a variety of settings as demonstrated in our publications. Over the years, Aerpio has studied Tie2 activation in multiple models of ARDS and sepsis with positive results. Hence, when the COVID pandemic arrived, we already had significant preclinical data supporting our hypothesis on why it might be very effective. In addition, Aerpio’s Tie2 activators have the potential to treat multiple diseases where the underlying pathology is driven by unstable vessels. This disease does also include diabetic nephropathy where we have another pipeline candidate. However, before discussing our preclinical programs, I want to remind investors that we have a third drug candidate in clinical development, which is partnered with Gossamer Bio. The drug candidate is GB004, and it is a hypoxia inducible factor, or HIF activator, that is being developed for ulcerative colitis by our partner in Gossamer. Now, Gossamer just recently indicated that it plans to initiate a 12-week Phase II trial in patients with mild-to-moderate ulcerative colitis in the second half of 2020. So they have moved up their time line. Investors may benefit from this program as well because our deal terms specify that Aerpio has a 20% participation right in any transaction on this program. For example, if Gossamer sells the program to a third party, Aerpio will receive 20% of those proceeds. Now I would like to switch back to Tie2 activation and describe our preclinical programs. In a recently completed Phase IIb study, razuprotafib demonstrated the ability to lower proteinuria as measured by decreasing urinary albumin creatinine ratio by about 20%, replicating a finding in a previous Phase II study. The decrease in proteinuria suggests that razuprotafib and our other Tie2 activating drug, the antibody ARP-1536, may have the potential to improve kidney function in diabetics, potentially delaying progression to kidney dialysis. The company’s second asset, ARP-1536, is a humanized monoclonal antibody observed to activate Tie2 receptors in a dose-dependent manner in preclinical models. Aerpio believes ARP-1536 holds potential as a monthly or biweekly systemic therapy to treat diabetic complications, including diabetic nephropathy. The company’s third asset is a bispecific antibody that binds both VEGF and VE-PTP, the phosphatase enzyme. And by doing so, it inhibits VEGF activation and activates Tie2. This bispecific antibody has the potential to be an improved product for treating wet age-related macular degeneration and diabetic macular edema. These antibodies would be dosed intravitreally into the eye in the same fashion as the current anti-VEGF drugs like EYLEA and LUCENTIS. That completes the description of our pipeline this morning. So, I would like to thank you for your attention during this call. We are excited about the prospects for Aerpio and believe that both our glaucoma program and COVID-19 programs could be transformative for the company. Over my career as a drug developer, I have never been more pleased or excited to be part of the Aerpio team. I will now turn the call back over to Gina to review the financials for the second quarter.